Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults

Objectives

The proposed study is a Phase 1 study with controlled human malaria infection (CHMI) designed primarily to evaluate the safety of Falciparum Malaria Protein 12 (FMP012) combined with the AS01B adjuvant system. The overall aim of this study is to evaluate the immunogenicity, efficacy and safety of this new vaccine candidate.